Loading organizations...
Innoskel is a technology company.
Innoskel is a pioneering platform biotechnology company dedicated to developing transformative therapies for rare skeletal disorders, specifically focusing on type 2 collagenopathies. The company's core approach involves advanced gene therapy candidates, with INS-101 identified as a primary asset. These therapies aim to address the significant unmet medical needs of individuals suffering from these debilitating genetic conditions through targeted biological interventions.
The company was founded by Dr. Elvire Gouze, a distinguished serial entrepreneur and recognized expert in the field of skeletal disorders. Dr. Gouze established Innoskel building upon her extensive experience and insight into the complexities of rare bone diseases, an insight deepened by her prior entrepreneurial ventures in the biotech sector. Her founding vision was to translate deep scientific understanding into effective treatments for conditions previously lacking adequate therapeutic options.
Innoskel serves patients afflicted with various rare skeletal disorders, particularly those stemming from type 2 collagenopathies. The company’s long-term vision is to bring forward novel therapeutic solutions that significantly improve the lives of these patients, transforming the treatment landscape for a group of conditions that currently present substantial clinical challenges and unmet needs. They are committed to advancing their pipeline to deliver meaningful outcomes.
Innoskel has raised $24.0M across 1 funding round.
Innoskel has raised $24.0M in total across 1 funding round.
Innoskel has raised $24.0M in total across 1 funding round.
Innoskel's investors include Vida Ventures, Rafaèle Tordjman, Turenne Capital.
Innoskel is a pioneering bioscience platform company developing gene therapies for rare skeletal disorders, particularly type 2 collagenopathies that affect connective tissues.[1][2][5] Its lead asset, INS-101 (also referred to as INS101), targets spondyloepiphyseal dysplasia congenita (SEDC), a severe condition causing dwarfism that impacts about 1 in 100,000 people worldwide, with preclinical studies showing strong efficacy.[1][5] Innoskel serves patients and families with these unmet needs, solving the lack of transformative treatments through advanced platforms, including CRISPR technology, and raised €20 million in Series A funding in December 2020 co-led by Jeito Capital and Vida Ventures.[1][3]
The company is expanding its pipeline to other rare bone disorders while engaging closely with patient communities, as highlighted by its leadership at conferences like the 2022 Achondroplasia Research Conference.[1]
Innoskel launched publicly in December 2020 with its €20 million Series A financing round, marking its entry as a focused biotech player in rare skeletal diseases.[1][2] While specific founders are not detailed in available sources, the company quickly expanded its leadership team by May 2021 to accelerate development of INS-101 and platform innovation, signaling early momentum in building expertise for gene therapy advancement.[1] Pivotal early traction came from proof-of-concept studies demonstrating compelling efficacy for its SEDC gene therapy, positioning it as a leader in addressing type 2 collagenopathies like SEDC, the second leading cause of dwarfism.[5]
Innoskel rides the wave of gene therapy and CRISPR advancements in rare diseases, where market forces like unmet needs in skeletal dysplasias (e.g., SEDC as a top dwarfism cause) create high demand for innovative platforms.[3][5] Timing aligns with surging biotech investment in precision medicine post-2020, as seen in its Series A amid a funding boom for orphan drugs, enabling rapid preclinical progress.[1][2] It influences the ecosystem by advancing non-FGFR skeletal dysplasia research, fostering patient hope, and expanding therapy options, potentially setting standards for collagenopathy treatments in a niche with few competitors.[1]
Innoskel's trajectory points to clinical advancement of INS-101, likely entering trials soon given preclinical strength and 2021 leadership bolstering, while pipeline growth targets more rare bone disorders.[1] Trends like CRISPR maturation and orphan drug incentives will propel it, amplifying influence in bioscience as therapies reach patients. As a post-Series A player in a high-need space, expect follow-on funding and partnerships to evolve its platform, delivering on the promise of transformative hope for rare skeletal conditions—echoing its launch as a pioneer.[1][3]
Innoskel has raised $24.0M across 1 funding round. Most recently, it raised $24.0M Series A in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2020 | $24.0M Series A | Vida Ventures, Rafaèle Tordjman | Turenne Capital |